Article Contents ::
- 1 Details About Generic Salt :: Aminoglu
- 2 Main Medicine Class::
- 3 (ah-MEE-no-glue-TETH-ih-mide) Cytadren Tablets 250 mg Class: Adrenal cortex suppressant Indications Suppression of adrenal function in patients with Cushing syndrome. Suppression of adrenal function in advanced breast carcinoma or metastatic prostate carcinoma. Contraindications Standard considerations. Route/Dosage Cushing Syndrome ADULTS: PO 250 mg q 6 hr. Titrate to adrenal response in increments of 250 mg/day q 1 to 2 wk. Max daily dose is 2000 mg. Dosage Adjusment ADULTS: PO Dosage reduction may be required for a Ccr < 10 mL/min; specific guidelines are not established. Discontinue therapy if patient develops severe rash or rash that lasts > 5 to 8 days. Therapy may be continued at a lower dose after resolution of mild to moderate skin rashes. Interactions CNS depressants Concurrent use with CNS depressants (eg, narcotics, analgesics, alcohol, antiemetics, benzodiazepines, sedatives, tranquilizers) may potentiate CNS effects. Dexamethasone, digitoxin, medroxyprogesterone, tamoxifen, theophylline, warfarin Aminoglutethimide increases oxidative metabolism of these drugs. Higher doses of these agents may be required to achieve therapeutic response during concomitant therapy. Lab Test Interferences None well documented. Adverse Reactions CARDIOVASCULAR: Orthostatic or persistent hypotension; tachycardia. CNS: Headache; dizziness; drowsiness; lethargy. DERMATOLOGIC: Morbilliform rash; pruritus. ENDOCRINE: Adrenocortical insufficiency; hypothyroidism; masculinization and hirsutism in females. GI: Low potential for nausea and vomiting; elevated LFTs; cholestatic jaundice. GU: Aminoglutethimide crosses the placenta and has caused pseudohermaphroditism in female infants whose mothers took this agent and anticonvulsants during pregnancy. MUSCULOSKELETAL: Myalgia. Precautions Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Cortical hypofunction: May cause adrenal cortical hypofunction, especially under conditions of stress. Hypotension: Aminoglutethimide may suppress aldosterone production by the adrenal cortex and may cause orthostatic or persistent hypotension. Monitor BP. PATIENT CARE CONSIDERATIONS Administration/Storage Adminster PO. Store at room temperature. Protect from light. Assessment/Interventions Adrenal function usually returns to normal within 36 to 72 hr of discontinuing aminoglutethimide, although recovery may be slower after prolonged therapy. Monitor plasma cortisol to assess response to therapy for suppression of adrenal function. Thyroid function may decrease during therapy. Monitor at baseline and throughout therapy. Some patients may require thyroid supplements. Monitor LFTs at baseline and throughout therapy. Monitor periodically for any electrolyte or hematologic changes. Patients may require replacement of mineralocorticoids with fludrocortisone. Patients may require replacement of glucocorticoids. Hydrocortisone 20 to 30 mg PO every morning replaces endogenous secretion. Discontinuation of aminoglutethimide and additional steroids may be required in situations that cause stress, such as shock, trauma, or infections. OVERDOSAGE: SIGNS & SYMPTOMS Ataxia, somnolence, lethargy, dizziness, fatigue, coma, hyperventilation, respiratory depression, nausea and vomiting, loss of sodium and water, hyponatremia, hypochloremia, hyperkalemia, hypoglycemia, hypovolemic shock caused by dehydration, hypotension Patient/Family Education May produce drowsiness or dizziness; use caution while driving or performing other tasks requiring alertness, coordination, or physical dexterity. May cause rash, fainting, weakness, or headache; notify health care provider if pronounced. Nausea and loss of appetite may occur during the first 2 wk of therapy; notify health care provider if these persist or become pronounced. Medicscientist Drug Facts
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Aminoglu
Main Medicine Class::
(ah-MEE-no-glue-TETH-ih-mide)
Cytadren
Tablets
250 mg
Class: Adrenal cortex suppressant
Indications Suppression of adrenal function in patients with Cushing syndrome.
Suppression of adrenal function in advanced breast carcinoma or metastatic prostate carcinoma.
Contraindications Standard considerations.
Route/Dosage
Cushing Syndrome
ADULTS: PO 250 mg q 6 hr. Titrate to adrenal response in increments of 250 mg/day q 1 to 2 wk. Max daily dose is 2000 mg.
Dosage Adjusment
ADULTS: PO Dosage reduction may be required for a Ccr < 10 mL/min; specific guidelines are not established.
Discontinue therapy if patient develops severe rash or rash that lasts > 5 to 8 days. Therapy may be continued at a lower dose after resolution of mild to moderate skin rashes.
Interactions
CNS depressants
Concurrent use with CNS depressants (eg, narcotics, analgesics, alcohol, antiemetics, benzodiazepines, sedatives, tranquilizers) may potentiate CNS effects.
Dexamethasone, digitoxin, medroxyprogesterone, tamoxifen, theophylline, warfarin
Aminoglutethimide increases oxidative metabolism of these drugs. Higher doses of these agents may be required to achieve therapeutic response during concomitant therapy.
Lab Test Interferences None well documented.
Adverse Reactions
CARDIOVASCULAR: Orthostatic or persistent hypotension; tachycardia. CNS: Headache; dizziness; drowsiness; lethargy. DERMATOLOGIC: Morbilliform rash; pruritus. ENDOCRINE: Adrenocortical insufficiency; hypothyroidism; masculinization and hirsutism in females. GI: Low potential for nausea and vomiting; elevated LFTs; cholestatic jaundice. GU: Aminoglutethimide crosses the placenta and has caused pseudohermaphroditism in female infants whose mothers took this agent and anticonvulsants during pregnancy. MUSCULOSKELETAL: Myalgia.
Precautions
Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Cortical hypofunction: May cause adrenal cortical hypofunction, especially under conditions of stress. Hypotension: Aminoglutethimide may suppress aldosterone production by the adrenal cortex and may cause orthostatic or persistent hypotension. Monitor BP.
PATIENT CARE CONSIDERATIONS
Administration/Storage
- Adminster PO.
- Store at room temperature. Protect from light.
Assessment/Interventions
- Adrenal function usually returns to normal within 36 to 72 hr of discontinuing aminoglutethimide, although recovery may be slower after prolonged therapy.
- Monitor plasma cortisol to assess response to therapy for suppression of adrenal function.
- Thyroid function may decrease during therapy. Monitor at baseline and throughout therapy. Some patients may require thyroid supplements.
- Monitor LFTs at baseline and throughout therapy.
- Monitor periodically for any electrolyte or hematologic changes.
- Patients may require replacement of mineralocorticoids with fludrocortisone. Patients may require replacement of glucocorticoids. Hydrocortisone 20 to 30 mg PO every morning replaces endogenous secretion. Discontinuation of aminoglutethimide and additional steroids may be required in situations that cause stress, such as shock, trauma, or infections.
OVERDOSAGE: SIGNS & SYMPTOMS
Ataxia, somnolence, lethargy, dizziness, fatigue, coma, hyperventilation, respiratory depression, nausea and vomiting, loss of sodium and water, hyponatremia, hypochloremia, hyperkalemia, hypoglycemia, hypovolemic shock caused by dehydration, hypotension
Patient/Family Education
- May produce drowsiness or dizziness; use caution while driving or performing other tasks requiring alertness, coordination, or physical dexterity.
- May cause rash, fainting, weakness, or headache; notify health care provider if pronounced.
- Nausea and loss of appetite may occur during the first 2 wk of therapy; notify health care provider if these persist or become pronounced.
Medicscientist Drug Facts
PATIENT CARE CONSIDERATIONS
OVERDOSAGE: SIGNS & SYMPTOMS | |
Ataxia, somnolence, lethargy, dizziness, fatigue, coma, hyperventilation, respiratory depression, nausea and vomiting, loss of sodium and water, hyponatremia, hypochloremia, hyperkalemia, hypoglycemia, hypovolemic shock caused by dehydration, hypotension |
Drugs Class ::
(ah-MEE-no-glue-TETH-ih-mide) |
Cytadren |
Tablets |
250 mg |
Class: Adrenal cortex suppressant |
Indications for Drugs ::
Indications Suppression of adrenal function in patients with Cushing syndrome.
Suppression of adrenal function in advanced breast carcinoma or metastatic prostate carcinoma.
Drug Dose ::
Route/Dosage
Cushing Syndrome
ADULTS: PO 250 mg q 6 hr. Titrate to adrenal response in increments of 250 mg/day q 1 to 2 wk. Max daily dose is 2000 mg.
Dosage Adjusment
ADULTS: PO Dosage reduction may be required for a Ccr < 10 mL/min; specific guidelines are not established.
Discontinue therapy if patient develops severe rash or rash that lasts > 5 to 8 days. Therapy may be continued at a lower dose after resolution of mild to moderate skin rashes.
Contraindication ::
Contraindications Standard considerations.
Drug Precautions ::
Precautions
Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Cortical hypofunction: May cause adrenal cortical hypofunction, especially under conditions of stress. Hypotension: Aminoglutethimide may suppress aldosterone production by the adrenal cortex and may cause orthostatic or persistent hypotension. Monitor BP.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CARDIOVASCULAR: Orthostatic or persistent hypotension; tachycardia. CNS: Headache; dizziness; drowsiness; lethargy. DERMATOLOGIC: Morbilliform rash; pruritus. ENDOCRINE: Adrenocortical insufficiency; hypothyroidism; masculinization and hirsutism in females. GI: Low potential for nausea and vomiting; elevated LFTs; cholestatic jaundice. GU: Aminoglutethimide crosses the placenta and has caused pseudohermaphroditism in female infants whose mothers took this agent and anticonvulsants during pregnancy. MUSCULOSKELETAL: Myalgia.
Drug Mode of Action ::
(ah-MEE-no-glue-TETH-ih-mide) |
Cytadren |
Tablets |
250 mg |
Class: Adrenal cortex suppressant |
Drug Interactions ::
Interactions
CNS depressants
Concurrent use with CNS depressants (eg, narcotics, analgesics, alcohol, antiemetics, benzodiazepines, sedatives, tranquilizers) may potentiate CNS effects.
Dexamethasone, digitoxin, medroxyprogesterone, tamoxifen, theophylline, warfarin
Aminoglutethimide increases oxidative metabolism of these drugs. Higher doses of these agents may be required to achieve therapeutic response during concomitant therapy.
Drug Assesment ::
Assessment/Interventions
- Adrenal function usually returns to normal within 36 to 72 hr of discontinuing aminoglutethimide, although recovery may be slower after prolonged therapy.
- Monitor plasma cortisol to assess response to therapy for suppression of adrenal function.
- Thyroid function may decrease during therapy. Monitor at baseline and throughout therapy. Some patients may require thyroid supplements.
- Monitor LFTs at baseline and throughout therapy.
- Monitor periodically for any electrolyte or hematologic changes.
- Patients may require replacement of mineralocorticoids with fludrocortisone. Patients may require replacement of glucocorticoids. Hydrocortisone 20 to 30 mg PO every morning replaces endogenous secretion. Discontinuation of aminoglutethimide and additional steroids may be required in situations that cause stress, such as shock, trauma, or infections.
|
Drug Storage/Management ::
Administration/Storage
- Adminster PO.
- Store at room temperature. Protect from light.
Drug Notes ::
Patient/Family Education
- May produce drowsiness or dizziness; use caution while driving or performing other tasks requiring alertness, coordination, or physical dexterity.
- May cause rash, fainting, weakness, or headache; notify health care provider if pronounced.
- Nausea and loss of appetite may occur during the first 2 wk of therapy; notify health care provider if these persist or become pronounced.
Medicscientist Drug Facts